114 related articles for article (PubMed ID: 10197410)
21. Low density lipoprotein-lowering and high density lipoprotein-elevating effects of nicardipine in rats.
Ohata I; Sakamoto N; Nagano K; Maeno H
Biochem Pharmacol; 1984 Jul; 33(14):2199-205. PubMed ID: 6466343
[TBL] [Abstract][Full Text] [Related]
22. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Hunninghake DB; Peters JR
Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
[TBL] [Abstract][Full Text] [Related]
23. Plasma protein concentrations in hypertriglyceridaemic subjects. Effect of clofibrate and comparison with normal subjects.
Ballantyne FC; Morrison BA; Ballantyne D; Dryburgh FJ; Epenetos AA
Clin Chim Acta; 1978 Jul; 87(1):43-7. PubMed ID: 668144
[TBL] [Abstract][Full Text] [Related]
24. Comparison of clofibrate and ethyl-5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate induced changes in serum lipoprotein cholesterol and hepatic peroxisome proliferation in the normal rat.
Stevens TJ; Stafford WW; Day CE; Block EM
Artery; 1983; 12(2):81-94. PubMed ID: 6678582
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and hypolipidemic evaluation of beta-alkylaminopropiophenone and beta-alkylaminopropio-2'-naphthone derivatives in rodents.
Huang Y; Hall IH
Pharmazie; 1996 Apr; 51(4):199-206. PubMed ID: 8628737
[TBL] [Abstract][Full Text] [Related]
26. Hypolipidaemic mechanisms of action of CM108 (a flavone derivative) in hyperlipidaemic rats.
Ji W; Guo L; Lian J; Gong B
J Pharm Pharmacol; 2008 Sep; 60(9):1207-12. PubMed ID: 18718125
[TBL] [Abstract][Full Text] [Related]
27. Potential hypolipidemic agents. 7. Synthesis and lipid-lowering properties of 2-(dibenzofuranyloxy)-2-methylpropionates and related compounds.
Bondesson G; Hedbom C; Högberg T; Magnusson O; Stjernström NE; Carlson LA
J Med Chem; 1974 Jan; 17(1):108-12. PubMed ID: 4808456
[No Abstract] [Full Text] [Related]
28. Synthesis and antilipidemic properties of cis-7-chloro-3a, 8b-dihydro-3a-methylfuro[3,4-b]benzofuran-3(1H)-one, a tricyclic clofibrate related lactone having a structural resemblance to mevalonolactone.
Witiak DT; Kuwano E; Feller DR; Baldwin JR; Newman HA; Sankrappa SK
J Med Chem; 1976 Oct; 19(10):1214-20. PubMed ID: 994152
[TBL] [Abstract][Full Text] [Related]
29. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
Kesäniemi YA; Grundy SM
JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
[TBL] [Abstract][Full Text] [Related]
30. Effects of S-8527 (1,1-bis4'-(1"-carboxy'1"-methylpropoxy)-phenyl)-cyclohexane), a new hypolipidemic compound, on triglyceride metablolism in rats.
Suzuki K
Biochem Pharmacol; 1975 Jun; 24(11-12):1203-7. PubMed ID: 237511
[No Abstract] [Full Text] [Related]
31. Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients.
Bagdade JD; Shantharam VV; Sollek M; Albers JJ
Clin Nephrol; 1979 Aug; 12(2):83-6. PubMed ID: 230927
[TBL] [Abstract][Full Text] [Related]
32. Effects of KRN4884, a novel pyridinecarboxamidine type KATP channel opener, on serum triglyceride levels in rats.
Yokoyama T; Izumi H; Endoh M; Izawa T; Ogawa N; Okada Y
Br J Pharmacol; 1997 Apr; 120(8):1471-6. PubMed ID: 9113367
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors.
Mendieta A; Jiménez F; Garduño-Siciliano L; Mojica-Villegas A; Rosales-Acosta B; Villa-Tanaca L; Chamorro-Cevallos G; Medina-Franco JL; Meurice N; Gutiérrez RU; Montiel LE; Cruz Mdel C; Tamariz J
Bioorg Med Chem; 2014 Nov; 22(21):5871-82. PubMed ID: 25311563
[TBL] [Abstract][Full Text] [Related]
34. Studies on antihyperlipidemic agents. II. Synthesis and biological activities of 2-chloro-3-arylpropionic acids.
Kawamatsu Y; Asakawa H; Saraie T; Imamiya E; Nishikawa K; Hamuro Y
Arzneimittelforschung; 1980; 30(4):585-9. PubMed ID: 7190396
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and hypolipidemic activity of 4-substituted 1-acyl-1,2,4-triazolidine-3,5-diones in rodents.
Simlot R; Izydore RA; Wong OT; Hall IH
J Pharm Sci; 1993 Apr; 82(4):408-15. PubMed ID: 8468686
[TBL] [Abstract][Full Text] [Related]
36. Hypolipemic activity of clofibrate-related compounds. 2nd Communication.
Metz G; Specker M
Arzneimittelforschung; 1977 Jul; 27(7):1421-4. PubMed ID: 578466
[TBL] [Abstract][Full Text] [Related]
37. [Effect of bis-(p-chlorophenoxy) acetic acid on serum lipids].
Göres E; Rösner G; Spittka K; Kienast S
Acta Biol Med Ger; 1976; 35(12):1745-7. PubMed ID: 1028331
[No Abstract] [Full Text] [Related]
38. Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.
Vázquez M; Merlos M; Adzet T; Laguna JC
Br J Pharmacol; 1996 Mar; 117(6):1155-62. PubMed ID: 8882610
[TBL] [Abstract][Full Text] [Related]
39. Clofibrate decreases jejunal cholesterol synthesis and activity of postheparin plasma lipoprotein lipase in the rat.
Strandberg TE; Kuusi T; Tilvis RS; Miettinen TA
Pharmacology; 1983; 26(5):290-6. PubMed ID: 6856670
[TBL] [Abstract][Full Text] [Related]
40. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats.
Mizuguchi K; Yano T; Kojima M; Tanaka Y; Ishibashi M; Masada A; Sato M; Mizota M; Fukutake K; Saito Y
Jpn J Pharmacol; 1992 Jul; 59(3):307-12. PubMed ID: 1434127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
